While confirming our findings in relation to the colon, they found other important differences. For the first time, CEA was detected in patients with non-enteric cancer by means of the CEA radioimmunoassay of sera. Moreover, as yet unexplained positive results occurred in patients with advanced alcoholic cirrhosis, pancreatitis and chronic renal failure in the absence of cancer.
More recently LoGerfo et al. (1971) , employing a zirconyl phosphate gel method of CEA radioimmunoassay, found circulating antigen in 88 out of 101 patients with colonic cancer. In contrast to our original results, nearly 80% of patients with upper digestive tract cancer and over 50% of patients with non-enteric cancer had detectable circulating CEA. These findings clearly indicate that a CEA-like antigen appears in the serum of patients with non-entodermally derived cancer. In 299 patients without apparent neoplasia, 11 false positive results were recorded; interestingly, all these occurred in patients over 51 years, an age group at great risk of occult neoplasms. Subsequent follow up has in fact shown the presence of occult neoplasia in 2 of these patients. In addition, circulating CEA was found in patients with active ulcerative colitis without neoplasia. In this condition, where there is a known predilection to develop colonic cancer, it is important to determine whether the elevated levels of CEA have any clinical significance. For example, does detectable CEA differentiate between those who will eventually develop colonic cancer and those who will remain cancer-free ? To date, all published studies have been primarily concerned with defining the assay's specificity. As yet, no detailed reports have appeared on the value of the assay as a diagnostic tool or as a monitor in patient management. Nevertheless, the potential diagnostic value of the CEA assay is illustrated by case histories previously reported (Thomson 1971). In these particular and selected clinical problems, the assay added a new dimension to the early detection of cancer when the physician dealt with the whole patient and in the context of all other information.
In our original study, we found that in patients with metastatic cancer circulating CEA remained elevated postoperatively, whereas, in patients with apparently localized tumours, resection of the lesion was accompanied by a fall in serum CEA to undetectable levels (Thomson et al. 1969 ). By monitoring the levels of circulating CEA after tumour resection, an early indication of regrowth as reflected by a rising CEA titre may be obtained and this should stimulate further therapeutic endeavours at a more amenable time.
At present there are two major drawbacks which make the assay unsuitable for general routine large-scale screening. First, the percentage of unexplained positives, although small, would represent an intolerable burden on medical facilities. Secondly, there is as yet no evidence that a large number of early, curable cases would be discovered. The lack of tumour specificity may be considered a major fault. However, this may be circumvented either by developing assays of different specificities or by detecting CEA in secretions from specific organ systems, such as urine, fices and sputum.
In summary, the CEA radioimmunoassay represents the first potentially useful tool for large-scale immunodiagnosis of cancer by the demonstration of a circulating tumour-associated antigen. The ultimate role of the CEA assay in clinical medicine, however, awaits a wider experience. Thomson 
Lymphocyte Sensitization in Malignant Neoplasia
In recent years relatively little attention has been devoted to cellular immunity in malignant disease (Klein 1970) compared with the mass of data derived from circulating antibody studies, reviewed by Southam (1967) . The widespread studies of carcinoembryonic antigen (Gold & Freedman 1965) largely involve the use of immunological methods to detect circulating antigen, rather than antibody, in patients with gastrointestinal malignant disease.
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In a study of lymphocyte sensitization, using a new and very sensitive method, in patients with cerebeilar degeneration or carcinomatous neuropathy, it was found that all patients with malignant disease had lymphocytes sensitized to encephalitogenic basic protein (EF) in common with those suffering from any form of destructive neurological disease . The present study extends this work using similar antigen or antigens extracted from tumour tissues ) and reviews the findings in the first 200 cases. Antigens were prepared as described by ; they consist of watersoluble basic proteins, mol. wt. from 15 000 to 20 000, and show several components on acrylamide gel electrophoresis. These tumour extracts may be further purified to show a single electrophoretic component (Carnegie et al. 1971) .
Lymphocyte sensitization to these antigens was measured using a cell electrophoresis technique. When a sensitized lymphocyte reacts with a specific antigen it liberates a series of substances (lymphokines) capable of blocking the normal migration of macrophages (David et al. 1964) ; the same or a closely related substance also reduces the electrophoretic mobility of macrophages (Diengdoh & Turk 1968 , 1972 . The macrophage can therefore be used as an indicator in this system. However, initial experiments showed that the lymphocytes contaminating macrophages (normal guinea-pig peritoneal exudate) reacted with foreign lymphocytes to give a mixed lymphocyte reaction, and that this very delicate system could only be made to work either by gradient fractionation of the exudate to remove the lymphocytes or by y irradiation to inactivate them. Lymphocytes from patients were mixed with an appropriate concentration of antigen and irradiated macrophage exudate (guinea-pig), and allowed to incubate at 18'C for 1I hours, after which the electrophoretic mobility of the macrophages was measured in a Zeiss cytopherometer at 23°C with phase optics to give ready identification of the macrophages, using only cells containing droplets of liquid paraffin and of average size. This instrument has a natural tendency to internal drifts and turbulence and readings must only be taken when the cells are under absolutely stable conditions. With practice, standard deviations of 3-4% with a maximum range of 10-15 % may be achieved. All results were expressed as a percentage slowing compared to a control lymphocyte macrophage *mixture without antigen; that is, [(mobility with antigen-control mobility)/control mobility] x 100. Between 16 and 20 samples for test were made up, randomized and measured blind in all cases. Further details are given by and .
Lymphocytes were isolated from the blood of patients known to be suffering from malignant disease by sedimentation of defibrinated blood with iron carbonyl and methyl cellulose. Also studied were cells from normal subjects, and from patients with neurological diseases, benign tumours (fibroadenoma of breast, fibroid), active tuberculosis, sarcoidosis, chronic bronchitis, and after massive surgery for non-malignant conditions. Table 1 shows the results of tests using antigens from 6 different tumours on patients with carcinoma and neurological disease. These indicate that in malignancy the response is greater to 'cancer' antigens than to nervous tissue antigen, and vice versa in neurological disease. In addition, the various tumour antigens behave identically and with no significant differences between them. Also, the response does not relate to the site of the patient's disease; for example, cells from a patient with carcinoma of the breast respond equally to extracts from breast, lung and stomach tumours. 12 5 % were all laboratory workers who had been exposed to nervous tissue antigens and Freund's adjuvant, which may account for their increased sensitization. The patients in the overlap area were suffering from advanced metastatic carcinoma and were known to have depressed delayed hypersensitivity responses which may have affected their cellular responses in the same way. One patient, referred as suffering from malaise, weight loss and general chronic illness, gave a completely negative result; his illness was finally diagnosed as aleukemic leukxemia. There appears to be no definite correlation between either the extent or the site of malignancy and the amount of cellular sensitization. It is still difficult to make an absolute diagnosis by this test in patients with neurological disease, sarcoidosis, disseminated lupus erythematosus and possibly active tuberculosis or rheumatoid arthritis. The differences are perhaps statistically significant in the first group if brain secondaries can be definitely excluded, but in the others arising from a general loss of immune discrimination or immunization with a very similar antigen, results must remain suggestive rather than certain. Benign tumours and chronic conditions have so far given negative results. In 7 cases giving a positive result the clinical diagnosis of malignancy remains in doubt; a further 3 cases were suffering from 'semi-malignant' conditions (plexiform neurofibroma, &c.).
The lymphocyte sensitization test can be applied to all cases of malignant neoplasia except the leukeemias, but not for the detection of recurrence or metastases. The cells, once sensitized, remain so for many years . Routine use of this technique presents considerable difficulty and precludes its applica, tion to screening; it is best applied in doubtful cases to detect a malignant process, but is regrettably not capable of localizing the lesion. Addendum (April 1972): One case with a doubtful diagnosis of malignancy has since been admitted with cancer of the large bowel. Increasing interest is being shown in the possibilities of using immunologically based procedures for the diagnosis and treatment of malignant disease. This communication describes a two-year, double-blind, controlled trial of an intradermal tumour test carried out on a series of 340 patients presenting with signs or symptoms suggesting the presence of a tumour.
The test employed developed from the work of Makari, who reported on the presence in carcinomatous patients of carcinoma-specific antigens (Makari 1955) and later extended his observations to both malignant and benign tumours (Makari 1958b). These antigens have been shown to be polysaccharide or glycoprotein in nature (Makari 1958a; Smith 1963, unpublished communication to USA Food and Drug Administration; Jeanloz 1970, personal communication to Dr J Goddard).
Makari originally used the highly sensitive Schultz-Dale technique using desensitization procedures to eliminate the interfering effects of normal antigens. However, technical difficulties severely restricted its potential as procedure for general use. An intradermal test procedure was, therefore, developed (Makari 1960 (Makari , 1962 . This was based on the injection into the skin of polysaccharide-containing fractions (referred to as tumour polysaccharidal substances or TPS) extracted from carcinomas, sarcomas and lymphomas, that were complexed with antibodies
